-
Original Article
-
Korean J Med. 2009;76(1):10-15.
- C형 간염 환자에서 페그인터페론과 리바비린 치료 후 생긴 돌발성 난청 1예
-
서정아, 문성수, 강현구, 김현주, 박성재, 이연재, 설상영
-
- Permanent sudden hearing loss associated with peginterferon and ribavirin combination therapy during hepatitis C treatment
-
Jeong Ah Seo, Sung Soo Moon, Hyoun Gu Kang, Hyun Ju Kim, Sung Jae Park, Youn Jae Lee, Sang Yong Seol
-
-
- Abstract
- Peginterferon and ribavirin combination therapy for chronic hepatitis C is associated with major adverse effects, and systemic
side effects are common. However, little is known about the influence of peginterferon on hearing loss, although it has been described
as a rare complication of standard interferon. A 65-year-old man with chronic hepatitis C (genotype 2) developed sudden
unilateral right-sided hearing loss just after finishing 24 weeks of treatment with peginterferon α 2a (180 µg/week) and ribavirin
(800 mg/day). The audiological examination revealed a right-sided sensorineural hearing loss. Auditory brain-stem response measures
confirmed the diagnosis. The hearing loss did not respond to corticosteroid therapy. The auditory disability remained unchanged
12 months after the end of treatment, although no HCV RNA was detectable 24 weeks after the end of treatment. We report
a patient who developed irreversible hearing loss just after completing treatment with peginterferon and ribavirin. (Korean J Med
76:S10-S14, 2009)
Keywords :Chronic hepatitis C, Peginterferon, Sudden hearing loss
